The liver can regenerate itself — mostly. When damage passes a certain threshold, even that capacity runs out, and the only remaining option is a transplant. About 9,000 to 10,000 Americans are on the liver transplant list at any given time. Roughly 20 percent become too sick to receive a donated organ, or die waiting. Wyss Institute
A team at the Wyss Institute at Harvard University, Boston University, and MIT is proposing a different approach. Instead of trying to build large tissue constructs in the lab — the approach the field has struggled with for years — they implant a small one, then trigger it to grow on demand inside the body. They call the strategy BOOST: bioengineered on-demand outgrowth via synthetic biology triggering. Their results in mice are published this week in Science Advances. Science Advances
The core problem in regenerative liver medicine has always been scale. Lab-grown tissues can be made only so large before they outstrip the oxygen and nutrient diffusion limits of what can survive without active blood supply. BOOST sidesteps that constraint by making the body itself the bioreactor.
The research, led by Christopher Chen and Sangeeta Bhatia, and spearheaded by Amy Stoddard, started with a practical question: what if you didn't have to solve the scale problem in the lab at all? What if a small implant could be triggered to expand after it's already engrafted? Wyss Institute
The answer turned out to require solving two sub-problems. The first was identifying the right growth signals. The team screened a panel of candidate growth factors and settled on four — HGF, TGFa, WNT2, and RSPO3 — that potently induced sparse hepatocyte cultures to proliferate. The catch: they didn't work in densely packed 3D tissues, which is the relevant configuration for anything clinically useful. Wyss Institute
The second problem was a density checkpoint. When hepatocytes are packed together at realistic tissue densities, a protein called YAP gets squeezed out of the nucleus and degraded in the cytoplasm. YAP is a mechanical sensor; it's part of how cells sense whether there's room to divide. In high-density conditions, the signal is "stop." The team's solution was to engineer hepatocytes that express a non-degradable version of YAP — one that reaches the nucleus regardless of mechanical crowding — combined with the four growth factors. Both inputs proved necessary. Wyss Institute
They packaged the system using synthetic biology: fibroblasts engineered to secrete each of the four growth factors, hepatocytes expressing the modified YAP, and all of it kept under doxycycline control. Add doxycycline, the genes activate and the tissue expands. Remove it, and expansion stops. In culture, seven days of doxycycline treatment produced robust proliferation; withdrawal returned cells to a quiescent state. Wyss Institute
In mice, the same approach produced liver tissue that expanded after implantation. The implanted tissue exhibited a striking 500 percent increase in proliferation with a doubling of the engineered hepatocytes, and it was vascularized to accommodate the metabolic demand. No tumors, no fibrosis, no immune invasion. The mice were healthy. Critically — they were not injured. Prior work always required damaging the host liver to trigger hepatocyte engraftment. BOOST did not. Wyss Institute
The trade-off the team documented: rapidly proliferating hepatocytes showed reduced functional gene expression compared to their non-expanded counterparts. "High proliferation rates went hand in hand with a less functional HEP state," Stoddard noted. The team attributes this to a general biological trade-off seen across many proliferating cell types, and says they are working on restoring function after expansion using liver's native re-functionalization signals. Wyss Institute
The 20 percent mortality figure on the transplant waitlist is a real human cost. BOOST is an early answer to a real problem. But it is an answer in mice, not yet in any larger animal, let alone a human trial. The gap between a controllable genetic circuit in a mouse liver and a therapeutic intervention is the gap this field has been trying to cross for a decade.
What BOOST adds is a cleaner reframing of where the hard problem actually sits. Scale was the wrong problem to solve in the lab. Growing tissue on demand inside the body — if it translates — changes the geometry of the challenge entirely.
